Cowen and Company reiterated their hold rating on shares of Qiagen N.V. (NASDAQ:QGEN) in a research report sent to investors on Friday, November 3rd. Cowen and Company currently has a $33.00 price target on the stock.
Several other research analysts have also recently issued reports on the stock. Morgan Stanley reissued an overweight rating and set a $37.00 target price (up previously from $36.00) on shares of Qiagen N.V. in a report on Monday, July 10th. Zacks Investment Research raised shares of Qiagen N.V. from a sell rating to a hold rating and set a $38.00 target price for the company in a report on Wednesday, July 12th. Wells Fargo & Company reissued a market perform rating and set a $31.00 target price (up previously from $28.00) on shares of Qiagen N.V. in a report on Thursday, July 13th. Bank of America Corporation reaffirmed a neutral rating and issued a $36.00 price objective (up previously from $33.00) on shares of Qiagen N.V. in a report on Friday, July 21st. Finally, TheStreet cut shares of Qiagen N.V. from a b rating to a c+ rating in a report on Thursday, July 27th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have assigned a buy rating to the stock. Qiagen N.V. has an average rating of Hold and a consensus price target of $34.06.
Qiagen N.V. (NASDAQ:QGEN) traded down $0.77 during midday trading on Friday, hitting $30.77. 1,915,500 shares of the company’s stock were exchanged, compared to its average volume of 966,734. The stock has a market capitalization of $7,180.41, a PE ratio of 25.64, a P/E/G ratio of 1.93 and a beta of 1.13. Qiagen N.V. has a fifty-two week low of $27.51 and a fifty-two week high of $36.34. The company has a current ratio of 5.33, a quick ratio of 4.78 and a debt-to-equity ratio of 0.68.
Qiagen N.V. (NASDAQ:QGEN) last posted its quarterly earnings results on Monday, November 6th. The company reported $0.32 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.32. Qiagen N.V. had a net margin of 6.40% and a return on equity of 11.36%. The business had revenue of $364.00 million during the quarter, compared to analysts’ expectations of $363.42 million. During the same quarter last year, the company posted $0.29 earnings per share. The business’s quarterly revenue was up 7.5% on a year-over-year basis. sell-side analysts forecast that Qiagen N.V. will post 1.25 earnings per share for the current year.
A number of institutional investors and hedge funds have recently bought and sold shares of QGEN. Prudential Financial Inc. acquired a new position in Qiagen N.V. during the first quarter worth about $207,000. Teachers Advisors LLC boosted its position in Qiagen N.V. by 7.5% during the first quarter. Teachers Advisors LLC now owns 256,353 shares of the company’s stock worth $7,427,000 after acquiring an additional 17,892 shares during the last quarter. Geode Capital Management LLC boosted its position in Qiagen N.V. by 14.9% during the first quarter. Geode Capital Management LLC now owns 509,572 shares of the company’s stock worth $14,762,000 after acquiring an additional 65,924 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in Qiagen N.V. by 0.4% during the first quarter. Dimensional Fund Advisors LP now owns 73,215 shares of the company’s stock worth $2,121,000 after acquiring an additional 306 shares during the last quarter. Finally, BlackRock Inc. boosted its position in Qiagen N.V. by 8,793.4% during the first quarter. BlackRock Inc. now owns 7,839,636 shares of the company’s stock worth $227,114,000 after acquiring an additional 7,751,485 shares during the last quarter. Hedge funds and other institutional investors own 60.47% of the company’s stock.
About Qiagen N.V.
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Receive News & Ratings for Qiagen N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen N.V. and related companies with MarketBeat.com's FREE daily email newsletter.